Premium
High incidence of meropenem resistance among α‐hemolytic streptococci in children with cancer
Author(s) -
Abe Masako,
Kamijo Takehiko,
Matsuzawa Shigeyuki,
Miki Jun,
Nakazawa Yozo,
Sakashita Kazuo,
Okabe Tadashi,
Honda Takayuki,
Mitsuyama Junichi,
Koike Kenichi
Publication year - 2009
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.2008.02663.x
Subject(s) - meropenem , medicine , piperacillin/tazobactam , febrile neutropenia , piperacillin , neutropenia , antibiotics , minimum inhibitory concentration , vancomycin , incidence (geometry) , microbiology and biotechnology , hematology , antibiotic resistance , bacteria , chemotherapy , pseudomonas aeruginosa , staphylococcus aureus , biology , genetics , physics , optics
Background: Infections caused by antibiotics‐resistant Gram‐positive bacteria have been reported from many pediatric hematology–oncology centers. Methods: The susceptibility profiles to meropenem, piperacillin, and vancomycin among oral flora isolates of α‐hemolytic streptococci (AHS) obtained from six children with cancer who received several empirical therapies (ET) against febrile neutropenia, were investigated. Results: Meropenem minimum inhibitory concentration (MIC) of AHS isolated from ET patients was 2.167 ± 0.258 μg/mL (mean ± SD), which was significantly higher than the MIC of AHS isolated from control groups. Intriguingly, AHS isolated approximately 6 months after hospital discharge indicated recovery of susceptibility to meropenem. Conclusions: AHS isolates from neutropenic children with cancer should be checked for antibiotic susceptibility, even against carbapenems.